Foundational AI models for drug discovery have made a huge leap forward
over the last 2 years. However, limited availability of high-quality molecular data is a major bottleneck to achieving the next steps forward.
The AI Structural Biology Consortium was created to tackle these challenge and unblock the next revolutions in AI-driven drug discovery.
In this case study we explore:
- The challenges around access to high-quality molecular data for Life Sciences
- How the Consortium consisting of major pharmaceutical companies, prestigious model building partners and Apheris as the technology provider was created to tackle this
- The use cases including model benchmarking & fine-tuning
- Leveraging Federation to ensure secure, governed and privacy preserving collaboration between all parties